Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Prescription Patterns in Management of Heart Failure and Its Association With Readmissions: A Retrospective Analysis.

    Sep 25, 2024DOI: 10.1016/j.cardfail.2024.08.059Journal ArticleJCF

    Written by: Simran AgrawalZayd AlhaddadSarah NabiaObaid Ur RehmanMadiha KiyaniAjay KumarNripesh RegmiAdhvithi PingiliTushar GargRakesh AllamaneniAmrit PaudelGreg C FonarowAnup Agarwal

    Find these authors on Roon

    SA
    Dr. Simran Agrawal
    Advanced Heart Failure · Medstar Union Memorial Hospital

    Summary

    BACKGROUND: The American Heart Association/American College of Cardiology/Heart Failure Society of America recently added sodium-glucose cotransporter-2 inhibitors in addition to renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists to form the 4 pillars of guideline-directed medical therapy (GDMT) for the management of heart failure with reduced ejection fraction (HFrEF). Despite strong evidence suggesting improved outcomes with inpatient initiation of GDMT at target doses, significant lag has been noted in prescription practices. We sought to study GDMT prescription rates in patients with HFrEF at the time of hospital discharge and evaluate its association with various patient characteristics and all-cause readmission rates.METHODS AND RESULTS: We used a modified version of Heart Failure Collaboratory (HFC) score to characterize patients into 2 groups (those with an HFC score of <3 and an HFC score of ≥3) and to examine various socioeconomic and biomedical factors affecting GDMT prescription practices. Out of the eligible patients, the prescription rates for beta-blockers was 77.9%, renin-angiotensin-aldosterone system inhibitor was 70.3%, and mineralocorticoid receptor antagonists was 41%. Furthermore, prescription rates for sacubitril/valsartan was 27.7% and sodium-glucose cotransporter-2 inhibitors was 17%. Only 1% of patients had an HFC score of 9 (drugs from all 4 classes at target doses). Patients of black ethnicity, those admitted on teaching service and those with HFrEF as the primary cause of admission were more likely to have an HFC of ≥3 at discharge. An HFC of ≥3 was associated with lower rates of 1-month all-cause readmissions.CONCLUSIONS: Consistent with the prior research, our data show significant gaps in prescription of GDMT in HFrEF. Further implementation research should be done to improve GDMT prescription during inpatient stay.
    SA

    Dr. Simran Agrawal

    Cardiology · Advanced Heart Failure & Transplantation
    MedStar Union Memorial Hospital
    simrana